Abstract: Peptides of the general formulaH.sub.2 N-(Ch)-Arg-Gly-Asp-(Cx)-Hand the derivatives thereof described herein, wherein (Cx) and (Ch) each contains 1 to 20 amino acid residues and (Ch) contains at least one Lys or Arg residue, or at least one of each, inhibit platelet-fibrinogen binding and platelet-platelet aggregation and are thus useful inhibitors of cell adhesion.

Abstract: Conjugates are provided which are covalently bonded conjugates of an anticoagulant and protein that are prepared in the presence of a coupling agent that forms amide linkages between the anticoagulant and the protein. Such amide linking coupling agents exclude highly toxic coupling agents such as CNBr. These conjugates are useful for enhancing the blood compatibility of certain surfaces of a prosthetic device, a surgical apparatus, or an extra-corporeal medical device.

Abstract: The invention relates to a process for producing FVIII/vWF complexes for therapeutical use possessing both haemophilic A activity and Willebrand activity as well as a high degree of purity, such process substantially comprising the steps of fixing the FVIII/vWF complex in physiological conditions on a particular monoclonal antibody and releasing said complex by means of a suitable elution medium having no effct on the functions of the FVIII/vWF complex but able to dissociate the bonds linking the selected monoclonal anitbody to the FVIII/vWF complex, then collecting the latter in a highly purified form.

Abstract: Conjugates are provided which are covalently bonded conjugates of an anticoagulant and protein that are prepared in the presence of a coupling agent that forms amide linkages between the anticoagulant and the protein. Such amide linking coupling agents exclude highly toxic coupling agents such as CNBr. These conjugates are useful for enhancing the blood compatibility of certain surfaces of a prosthetic device, a surgical apparatus, or an extra-corporeal medical device.

Abstract: This invention concerns a method of preparing a cryoprecipitated suspension containing fibrinogen and Factor XIII useful as a precursor in the preparation of a fibrin glue which involves (a) freezing fresh frozen plasma from a single donor such as a human or other animal, e.g. a cow, sheep or pig, which has been screened for blood transmitted diseases, e.g. one or more of syphilis, hepatitis or acquired immune deficiency syndrome at about =80.degree. C. for at least about 6 hours, preferably for at least about 12 hours; (b) raising the temperature of the frozen plasma, e.g. to between about 0.degree. C. and room temperature, so as to form a supernatant and a cryoprecipitated suspension containing fibrinogen and Factor XIII; and (c) recovering the cryoprecipitated suspension.

Abstract: Treatment of cellular disorders involving abnormal solid cellular growths involves introduction of cytotoxic reagents dispersed in a physiologically acceptable proteinaceous matrix into the solid cellular growth or area of an existing or removed solid cellular growth. Enhanced effectiveness of the drug is observed, with reduced cytotoxic effects on cells distant from the site of introduction. Other drugs may be included to enhance therapeutic gain and reduce adverse affects to normal tissue.

Abstract: The peptide X-Arg-Gly-Asp-Ser-Y wherein X is H or at least one amino acid and Y is OH or at least one amino acid having the same cell-attachment activity as fibronectin.

Abstract: Highly purified, biologically active Human Factor VIII:C having specific activities of about 4000-8000 units per milligram of protein is prepared. In the method of preparation, an AHF concentrate is solubilized or equilibrated in an aqueous medium and treated to change the effective Stokes' radius of the Factor VIII:C to an apparently low value and then subjected to a separation from the concentrate. Treatment of the highly purified Factor VIII:C with a mixture of glycosidases causes substantial removal of carbohydrate side chains without reduction of procoagulant activity and with retention of significant in vivo survival time.

Abstract: A protein-polysuccinimide complex wherein a biologically active protein is combined with a polysuccinimide having a mean molecular weight of 2,000 to 1,000,000 and consisting of constitutive units represented by the following formulae: ##STR1## Said complex can be labelled with a radio-metal and can be used as a radioactive diagnostic in the field of nuclear medicine.

Abstract: Compositions containing therapeutically or immunologically active proteins are rendered substantially free from infectious agents such as viable viruses and bacteria without substantial loss of therapeutic or immunologic activity by mixing the protein composition with a complex formed from source of transition metal ions, such as copper ions, and an angularly-fused, polynuclear heterocyclic arene having two nitrogen atoms in a "cis-ortho" relationship, such as phenanthroline, and a reducing agent such as a thiol in amounts and at a temperature and for a time sufficient to inactivate substantially all of the viruses and bacteria contained therein. Compositions containing therapeutically active proteins substantially free from viral and bacterial infectivity, which have heretofore been unattainable, can be prepared by the method of the invention.

Abstract: Conjugates are provided which are covalently bonded conjugates of an anticoagulant and protein that are prepared in the presence of a coupling agent that forms amide linkages between the anticoagulant and the protein. Such amide linking coupling agents exclude highly toxic coupling agents such as CNBr. These conjugates are useful for enhancing the blood compatibility of certain surfaces of a prosthetic device, a surgical apparatus, or an extra-corporeal medical device.